QuickView for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=A8AB09FA390A3AE4E0D1D6F38BF237B8;jsessionid=51586F57457820B19218871CCD1B1B0A;jsessionid=1378266A38B81A4711AC8DCC93F77B7F;jsessionid=73AC8971AD1AC6EB5D00E04011873BA7;jsessionid=43D5AF56343DF1EFFCC74D774C8BADF4;jsessionid=8C1D772D32B3114A31F3779BC5D53125;jsessionid=537B414C873435C717D7E04E42A8F59B;jsessionid=D3C5245E81D7A3B358070C63E454383F;jsessionid=720F37BE0B1FD1F62663B90133D7B11C;jsessionid=3F045E38CE19698C5A5F57C821BEFE34 (gene)

1. ATXN2 intermediate expansions in amyotrophic lateral sclerosis.
2. Missense mutation in ATXN2 gene (c.2860C > T) in an amyotrophic lateral sclerosis patient with aggre…
3. The RNA-binding protein and stress granule component ATAXIN-2 is expressed in mouse and human tissue…
4. Ataxin-2 gene: a powerful modulator of neurological disorders.
5. Antagonistic roles for Ataxin-2 structured and disordered domains in RNP condensation.

There were no clinical trials for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=A8AB09FA390A3AE4E0D1D6F38BF237B8;jsessionid=51586F57457820B19218871CCD1B1B0A;jsessionid=1378266A38B81A4711AC8DCC93F77B7F;jsessionid=73AC8971AD1AC6EB5D00E04011873BA7;jsessionid=43D5AF56343DF1EFFCC74D774C8BADF4;jsessionid=8C1D772D32B3114A31F3779BC5D53125;jsessionid=537B414C873435C717D7E04E42A8F59B;jsessionid=D3C5245E81D7A3B358070C63E454383F;jsessionid=720F37BE0B1FD1F62663B90133D7B11C;jsessionid=3F045E38CE19698C5A5F57C821BEFE34